当前位置: X-MOL 学术Immunity › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The First Shall (Be) Last: Understanding Durable T Cell Responses in Immunotherapy
Immunity ( IF 25.5 ) Pub Date : 2019-01-15 , DOI: 10.1016/j.immuni.2018.12.029
Daniela S. Thommen

Efforts to understand how cancer immunotherapy restores anti-tumor T cell responses have largely concentrated on assessing the reactivation of dysfunctional T cells. In this issue of Immunity, Kurtulus et al. (2019) and Siddiqui et al. (2019) provide evidence that durable anti-tumor responses require less differentiated T cells that express the transcription factor Tcf1 and sustain the tumor-reactive T cell pool.



中文翻译:

首先(最后):了解免疫疗法中的持久性T细胞反应

理解癌症免疫疗法如何恢复抗肿瘤T细胞反应的努力主要集中在评估功能异常T细胞的重新激活上。在本期《免疫》中,Kurtulus等人。(2019)和Siddiqui等。(2019)提供的证据表明,持久的抗肿瘤反应需要表达转录因子Tcf1并维持肿瘤反应性T细胞库的分化程度较低的T细胞。

更新日期:2019-01-15
down
wechat
bug